LU91504I2 - Ranolazine ou un de ses sels ou solvates - Google Patents

Ranolazine ou un de ses sels ou solvates

Info

Publication number
LU91504I2
LU91504I2 LU91504C LU91504C LU91504I2 LU 91504 I2 LU91504 I2 LU 91504I2 LU 91504 C LU91504 C LU 91504C LU 91504 C LU91504 C LU 91504C LU 91504 I2 LU91504 I2 LU 91504I2
Authority
LU
Luxembourg
Prior art keywords
ranolazine
solvate
salt
Prior art date
Application number
LU91504C
Other languages
English (en)
French (fr)
Other versions
LU91504I9 (enExample
Original Assignee
Roche Palo Alto Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91504(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Palo Alto Llc filed Critical Roche Palo Alto Llc
Publication of LU91504I2 publication Critical patent/LU91504I2/fr
Publication of LU91504I9 publication Critical patent/LU91504I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
LU91504C 1998-09-10 2008-12-03 Ranolazine ou un de ses sels ou solvates LU91504I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation
PCT/US1999/020967 WO2000013686A2 (en) 1998-09-10 1999-09-09 Sustained release ranolazine formulations

Publications (2)

Publication Number Publication Date
LU91504I2 true LU91504I2 (fr) 2009-02-03
LU91504I9 LU91504I9 (enExample) 2019-01-02

Family

ID=26796494

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91504C LU91504I2 (fr) 1998-09-10 2008-12-03 Ranolazine ou un de ses sels ou solvates

Country Status (33)

Country Link
US (14) US6303607B1 (enExample)
EP (3) EP1527779A1 (enExample)
JP (2) JP3745621B2 (enExample)
KR (1) KR100475759B1 (enExample)
CN (2) CN1193757C (enExample)
AR (3) AR022085A1 (enExample)
AT (2) ATE217794T1 (enExample)
AU (4) AU744071B2 (enExample)
BR (2) BR9913626A (enExample)
CA (2) CA2342390C (enExample)
CY (1) CY2008020I2 (enExample)
CZ (2) CZ301375B6 (enExample)
DE (3) DE69901570T2 (enExample)
DK (2) DK1109558T3 (enExample)
ES (2) ES2177346T3 (enExample)
FR (1) FR09C0001I2 (enExample)
GE (1) GEP20053420B (enExample)
HK (1) HK1044284B (enExample)
HU (2) HU224215B1 (enExample)
IL (6) IL141893A0 (enExample)
LU (1) LU91504I2 (enExample)
MX (2) MXPA01002599A (enExample)
NL (1) NL300371I2 (enExample)
NO (4) NO319434B1 (enExample)
NZ (2) NZ510384A (enExample)
PL (3) PL196263B1 (enExample)
PT (2) PT1096937E (enExample)
RU (2) RU2214233C2 (enExample)
SI (2) SI1096937T1 (enExample)
TR (2) TR200101262T2 (enExample)
TW (1) TWI241911B (enExample)
UA (2) UA67793C2 (enExample)
WO (2) WO2000013686A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
NZ520780A (en) * 2000-02-18 2006-04-28 Cv Therapeutics Inc Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
WO2002007716A2 (en) * 2000-07-21 2002-01-31 Cv Therapeutics, Inc. Method for treating angina
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
ES2314227T7 (es) * 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
MX2007008162A (es) * 2005-01-06 2007-07-24 Cv Therapeutics Inc Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina.
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
CN100522169C (zh) * 2005-07-04 2009-08-05 齐鲁制药有限公司 盐酸雷诺嗪缓释制剂及其制备方法
WO2007016350A2 (en) * 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
EP1998387B1 (en) * 2006-03-17 2015-04-22 Konica Minolta Holdings, Inc. Organic electroluminescent device, display and illuminating device
FI20060501A7 (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi mahalaukussa
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
CA2678272A1 (en) 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
EP2117549A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008109175A1 (en) * 2007-03-07 2008-09-12 Concert Pharmaceuticals, Inc. Deuterated piperazine derivatives as anti-anginal compounds
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
KR20100047190A (ko) * 2007-06-13 2010-05-07 오스펙스 파마슈티칼스, 인코포레이티드 치환 피페라진
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
EP2515880B1 (en) 2009-05-28 2019-11-27 Lupin Limited Novel pharmaceutical compositions of ranolazine
MX2012003362A (es) 2009-09-25 2012-06-27 Lupin Ltd Composicion de liberación sostenida de ranolazina.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
NO3175985T3 (enExample) 2011-07-01 2018-04-28
WO2013043925A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
WO2014176557A2 (en) * 2013-04-26 2014-10-30 Chanrx Corporation Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rythm in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) * 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
EP4456897A4 (en) 2021-12-31 2025-12-10 Tenax Therapeutics Inc ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
ES2177601T3 (es) * 1989-06-23 2002-12-16 Syntex Llc Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. .
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine

Also Published As

Publication number Publication date
US20040029890A1 (en) 2004-02-12
UA75027C2 (uk) 2006-03-15
NO20011191D0 (no) 2001-03-08
AU2008207707A1 (en) 2008-09-25
NO320986B1 (no) 2006-02-20
NO2009005I2 (enExample) 2010-06-28
DE69901570T2 (de) 2003-01-09
AU6142599A (en) 2000-03-27
ATE217794T1 (de) 2002-06-15
CZ2001879A3 (cs) 2001-08-15
NO2009005I1 (no) 2009-03-16
CN1354665A (zh) 2002-06-19
IL141892A (en) 2006-08-20
CZ301341B6 (cs) 2010-01-20
JP3745621B2 (ja) 2006-02-15
HUP0104088A2 (hu) 2002-05-29
ATE285774T1 (de) 2005-01-15
PL202207B1 (pl) 2009-06-30
BR9913553A (pt) 2001-10-23
WO2000013687A3 (en) 2000-06-29
NO20054324L (no) 2001-04-30
CA2342390C (en) 2006-08-29
CY2008020I1 (el) 2010-07-28
EP1527779A1 (en) 2005-05-04
DE69922964T2 (de) 2005-12-08
DK1096937T3 (da) 2005-05-09
US20040097514A1 (en) 2004-05-20
UA67793C2 (uk) 2004-07-15
KR20010089874A (ko) 2001-10-12
NZ510386A (en) 2003-08-29
IL180864A0 (en) 2007-07-04
US20060147521A1 (en) 2006-07-06
AU2008207703A1 (en) 2008-09-25
FR09C0001I1 (enExample) 2009-02-27
RU2207856C2 (ru) 2003-07-10
RU2214233C2 (ru) 2003-10-20
DE122008000065I1 (de) 2009-04-09
IL141893A (en) 2008-08-07
US6369062B1 (en) 2002-04-09
US20020090396A1 (en) 2002-07-11
FR09C0001I2 (enExample) 2009-12-18
HK1040060A1 (en) 2002-05-24
US6620814B2 (en) 2003-09-16
WO2000013686A3 (en) 2000-07-06
MXPA01002599A (es) 2005-02-17
WO2000013687A2 (en) 2000-03-16
US20030166659A1 (en) 2003-09-04
IL141893A0 (en) 2002-03-10
NO319434B1 (no) 2005-08-15
AR052921A1 (es) 2007-04-11
HK1044284B (zh) 2005-07-15
AR022085A1 (es) 2002-09-04
KR100475759B1 (ko) 2005-03-10
SI1096937T1 (en) 2005-04-30
WO2000013686A2 (en) 2000-03-16
TR200101262T2 (tr) 2001-12-21
NL300371I2 (nl) 2009-10-01
PT1109558E (pt) 2002-10-31
EP1109558B1 (en) 2002-05-22
AR053440A2 (es) 2007-05-09
TR200101261T2 (tr) 2002-05-21
CN1193757C (zh) 2005-03-23
PL196668B1 (pl) 2008-01-31
US20060217397A1 (en) 2006-09-28
US6617328B2 (en) 2003-09-09
CZ301375B6 (cs) 2010-02-03
NZ510384A (en) 2002-10-25
IL141892A0 (en) 2002-03-10
NO20011192D0 (no) 2001-03-08
EP1109558A2 (en) 2001-06-27
TWI241911B (en) 2005-10-21
US20030100566A1 (en) 2003-05-29
DK1109558T3 (da) 2002-08-26
NO20011192L (no) 2001-04-30
DE69922964D1 (de) 2005-02-03
CZ2001880A3 (cs) 2001-08-15
AU6036499A (en) 2000-03-27
US20030099705A1 (en) 2003-05-29
EP1096937A2 (en) 2001-05-09
GEP20053420B (en) 2005-01-25
US6525057B2 (en) 2003-02-25
HU224215B1 (hu) 2005-06-28
NO20011191L (no) 2001-04-30
AU744071B2 (en) 2002-02-14
PL347073A1 (en) 2002-03-11
SI1109558T1 (en) 2002-10-31
HUP0104088A3 (en) 2002-12-28
CY2008020I2 (el) 2010-07-28
MXPA01002598A (es) 2002-04-08
AU760435B2 (en) 2003-05-15
HUP0103844A2 (hu) 2002-04-29
US6852724B2 (en) 2005-02-08
LU91504I9 (enExample) 2019-01-02
ES2177346T3 (es) 2002-12-01
BR9913626A (pt) 2001-12-04
PL196263B1 (pl) 2007-12-31
US6503911B2 (en) 2003-01-07
CA2342390A1 (en) 2000-03-16
US6303607B1 (en) 2001-10-16
US20050059667A1 (en) 2005-03-17
NL300371I1 (nl) 2009-02-02
PT1096937E (pt) 2005-04-29
CN1211086C (zh) 2005-07-20
HUP0103844A3 (en) 2002-11-28
US20050153982A1 (en) 2005-07-14
EP1096937B1 (en) 2004-12-29
CA2343376A1 (en) 2000-03-16
JP2002524416A (ja) 2002-08-06
CN1321088A (zh) 2001-11-07
JP2006096757A (ja) 2006-04-13
HK1044284A1 (en) 2002-10-18
DE69901570D1 (de) 2002-06-27
ES2234302T3 (es) 2005-06-16
CA2343376C (en) 2007-01-09
IL175371A0 (en) 2006-09-05
US20020004506A1 (en) 2002-01-10
US6562826B1 (en) 2003-05-13
EP1096937B9 (en) 2007-02-28
PL348249A1 (en) 2002-05-20
US6864258B2 (en) 2005-03-08

Similar Documents

Publication Publication Date Title
NL300371I2 (nl) Ranolazine of een zout of solvaat daarvan
DE69921712D1 (de) Kapazitiver Abstandssensor
NO984772L (no) Tidlig evalueringssystem med boreevne
DE69614974D1 (de) Drehbohrhammer
DE59914142D1 (de) Bohrhammer
LU91540I2 (fr) Robenacoxib-Onsior ou un de ses sels ou prémédicament vétérinairement acceptable
FIU980316U0 (fi) Oviesteen tunnistin
DE69943115D1 (de) Flüssigkeitsstandsgeber
BR9607388A (pt) Ferramenta de furos verticais
PT958198E (pt) Garrafa com parede dupla
DE69938221D1 (de) Positionssensor
DE69937621D1 (de) Löschbares bildformendes Material
FI982738A0 (fi) Lähettimen linearisointi
DK1089996T3 (da) Paroxetin-methansulfonat-acetonitril-solvat 1:1
DE59710762D1 (de) Berührungslos arbeitender wegmessensor
DE69805889D1 (de) Schneidtiefenbegrenzer
DK0778391T3 (da) Roterende slag-sneglebor
DE69934776D1 (de) Positionssensor
DE69902928D1 (de) Ultraschallsverbindungsverfahren
BR9913430B1 (pt) aparelhagem de profundidade de poÇo.
FI964091A7 (fi) Vedensyvyysmittari
DE59505872D1 (de) Schlag- oder Drehschlaghammer
DE69941245D1 (de) Kapazitiver sensor
DE59910240D1 (de) Kapazitiver Sensor
ITMI992509A0 (it) Strumento di livello